Table 3

Sex-specific multivariable-adjusted* regressions for fat depot volumes with adipokines

Women
Men
P
Effect sizeR2 (%)PEffect sizeR2 (%)P
Adiponectin§
    Visceral fat−2.1 (−1.5 to −2.7)13<0.001−1.1 (−0.7 to −1.5)10<0.001<0.001
    Subcutaneous fat−1.2 (−0.6 to −1.8)6<0.0010.1 (−0.3 to 0.5)40.540.001
    Pericardial fat−1.2 (−0.6 to −1.8)6<0.001−0.6 (−0.2 to −1.0)60.0050.03
    Intrathoracic fat−1.2 (−0.6 to −1.8)5<0.001−0.9 (−0.5 to −1.3)8<0.0010.07
Log resistin
    Visceral fat1.06 (1.03–1.10)6<0.0011.04 (1.00–1.08)30.070.15
    Subcutaneous fat1.06 (1.03–1.10)6<0.0011.05 (1.01–1.10)40.0080.88
    Pericardial fat1.04 (1.00–1.08)50.031.05 (1.01–1.10)40.010.77
    Intrathoracic fat1.06 (1.02–1.09)60.0021.07 (1.03–1.11)50.0020.43
  • *Adjusted for age, smoking, alcohol use, menopausal status (women only), and hormone replacement therapy (women only).

  • †Effect size refers to the average change in adiponectin or resistin concentration per SD of visceral, subcutaneous, pericardial, or intrathoracic fat volume. Effect sizes for log resistin were back transformed to a nonlogarithmic scale.

  • P value for sex interaction obtained from multivariable regression analysis on entire sample, adjusted for sex, age, smoking, alcohol use, menopausal status (women only), hormone replacement therapy (women only), and a sex-by-fat interaction term.

  • §R2 of model with covariates only is 2% in women and 4% in men.

  • R2 of model with covariates only is 4% in women and 3% in men.